Insulin biosimilars - Bioton

Drug Profile

Insulin biosimilars - Bioton

Alternative Names: Insulin analogues; Recombinant insulins

Latest Information Update: 15 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BIOTON
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Diabetes mellitus

Most Recent Events

  • 20 Jun 2018 Biomm plans a phase I trial for Type-1 diabetes mellitus in comparison with Humulin® in Brazil (RBR7mvgfc)
  • 22 May 2018 BIOMM S.A and Instituto de Ciências Farmacêuticas de Estudos e Pesquisas Ltda plans a phase I trial for type 1 Diabetes mellitus in Brazil (RBR8b9npb)
  • 31 Oct 2012 Actavis has been acquired and merged into Watson Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top